SonoVascular Completes First Close of Series A Preferred Stock Financing

Medical device company raises $6 million to advance ultrasound-based thrombectomy system for treating venous thromboembolism

Feb. 4, 2026 at 12:47am

Got story updates? Submit your updates here. ›

SonoVascular, Inc., a clinical stage medical device company focused on transforming the treatment of venous thromboembolism (VTE) with its SonoThrombectomy™ System, has completed the first close of its $6 million Series A preferred stock financing. Harbright Ventures, based in Cary, NC, is serving as lead investor, and Robert Ross, Founding Partner at Harbright, has joined SonoVascular's Board of Directors. The SonoThrombectomy System is an ultrasound facilitated, thrombolytic enhanced thrombectomy system that utilizes microbubble-mediated cavitation as a core mechanism of action.

Why it matters

SonoVascular's SonoThrombectomy System has the potential to redefine how clinicians approach clot management, offering a transformative alternative to today's standard of care for treating deep vein thrombosis (DVT) and pulmonary embolism (PE). Existing thrombectomy technologies carry inherent trade-offs, including blood loss and risk of vascular damage, but the SonoThrombectomy System demonstrated a favorable safety profile and consistent procedural performance in a First-In-Human feasibility study.

The details

In the First-In-Human study, the SonoThrombectomy System achieved a complete 100% Marder score (clot) reduction in all ten treated patients, with no device-related adverse events. Follow-up at both 30-days and 6-months confirmed significant and sustained improvements from baseline in Post-Thrombotic Syndrome (PTS) severity scores. The Series A financing will fund achievement of two key milestones in 2026: securing FDA approval for a U.S. based Peripheral Venous pivotal study and conducting a First-In-Human study for Pulmonary Embolism treatment.

  • SonoVascular completed the first close of its $6 million Series A preferred stock financing on February 3, 2026.
  • The company successfully treated ten patients in South America in its First-In-Human study for deep vein thrombosis (DVT).

The players

SonoVascular, Inc.

A clinical stage medical device company focused on transforming the treatment of venous thromboembolism (VTE) with its SonoThrombectomy™ System.

Harbright Ventures

An early-stage venture capital/private equity firm based in Cary, NC that is serving as the lead investor in SonoVascular's Series A financing.

Robert Ross

Founding Partner at Harbright Ventures who has joined SonoVascular's Board of Directors.

Dr. Lisandro Carnero-Vidal

Principal Investigator and Vascular Surgeon at Clínica La Sagrada Familia in Buenos Aires, Argentina who led the First-In-Human feasibility study of the SonoThrombectomy System.

Got photos? Submit your photos here. ›

What they’re saying

“There is currently no ideal device for the treatment of deep vein thrombosis, as existing technologies carry inherent trade-offs, including blood loss and risk of valvular or endothelial injury. In this First-In-Human feasibility study, the SonoThrombectomy System demonstrated a favorable safety profile and consistent procedural performance in patients with deep vein thrombosis.”

— Dr. Lisandro Carnero-Vidal, Principal Investigator and Vascular Surgeon

“SonoVascular has the rare combination of breakthrough technology and the experienced leadership necessary to redefine the standard of care in VTE. We led this round because SonoVascular is solving the 'trade-off' problem that has plagued DVT treatment for years - achieving total clot reduction without the typical risks of blood loss or vessel damage. With exceptionally strong FIH results, we believe this system is well-positioned to become the new standard of care.”

— Robert Ross, Founding Partner

What’s next

The Series A round will fund achievement of two important milestones during 2026: (i) secure FDA approval for a U.S. based Peripheral Venous pivotal study; and (ii) conduct a First-In-Human study for Pulmonary Embolism treatment.

The takeaway

SonoVascular's ultrasound-based thrombectomy system has the potential to transform the treatment of venous thromboembolism by providing a safer and more effective alternative to current therapies, which often involve trade-offs such as blood loss and vascular damage. The strong initial results and experienced leadership team position the company well to become the new standard of care for managing deep vein thrombosis and pulmonary embolism.